INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH

WHO Approves Single-Dose Cecolin HPV Vaccine Following Landmark Trial

7 months ago

• The WHO has approved Cecolin, a bivalent HPV vaccine, for single-dose use, potentially revolutionizing cervical cancer prevention efforts globally. • A clinical trial (CVIA 087) conducted by icddr,b and partners demonstrated the safety and efficacy of single-dose Cecolin vaccination. • The approval aims to address vaccine supply challenges and improve access in low- and middle-income countries, where 90% of cervical cancer deaths occur. • Health officials urge vaccination for girls aged 10-14, highlighting it as a critical opportunity to protect against HPV-related cervical cancer.

Dengue Vaccine Trial in Bangladesh Stalls Due to Funding Shortage Despite Promising Phase II Results

8 months ago

• Phase III clinical trials for the tetravalent dengue vaccine candidate, TV005, are stalled in Bangladesh due to a lack of funding, despite favorable Phase II results. • The TV005 vaccine, developed by the NIH, has shown effectiveness against all four dengue serotypes, including the currently dominant DEN-2 strain in Bangladesh. • While Phase III trials are underway in India and Brazil, the vaccine's availability in Bangladesh is projected to take three to five years without adequate financial backing. • Scientists warn that the DEN-2 serotype, which accounted for approximately 69% of dengue cases from July to September 2024, continues to pose a threat, especially outside Dhaka.